Upfront Briefing
Gilead went shopping in synthetic lethality, striking a $1.5B deal with China’s Genhouse to add an oncology asset to the pipeline.
On the regulatory tape, the FDA refused to review Moderna’s mRNA flu vaccine and issued a Complete Response Letter to Disc — a reminder that “platform” stories still need clean filing execution (and a receptive reviewer).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,836.2 |
+0.1% |
(0.1%) |
| Nasdaq 100 |
24,732.7 |
+0.2% |
(2.0%) |
| Russell 2000 |
2,646.7 |
+1.2% |
+6.6% |
| Healthcare (XLV) |
157.7 |
+1.1% |
+1.9% |
| Biotech (XBI) |
122.9 |
(0.3%) |
+0.8% |
| Nasdaq Biotech (NBI) |
5,917.2 |
+1.0% |
+3.7% |
| Clinical Trials (BBC) |
39.9 |
(1.1%) |
+3.4% |
|
- Small-caps outperformed (Russell 2000 +1.2%) as risk appetite skewed toward cyclicals, while defensives also bid (XLV +1.1%).
- Biotech lagged (XBI (0.3%)) despite NBI +1.0% — consistent with investors discounting near-term FDA headline risk (Moderna/Disc) more heavily in SMID biotech.
- Market data reflects U.S. close Fri 13-Feb-2026 (U.S. markets were closed Mon 16-Feb for Presidents’ Day).
The Big 3
|
1
|
Gilead strikes $1.5B synthetic lethal therapy deal with Genhouse
|
- Gilead struck a synthetic-lethality licensing deal with China’s Genhouse for GH31, paying $80M upfront plus up to $1.45B in milestones and tiered royalties.
- Why it matters: Another signal that China-sourced, clinical-ready oncology assets are now “mainstream BD” — and Gilead is leaning on licensing to refresh oncology depth without paying M&A control premiums. Watch for (i) how quickly GH31 moves into global trials and (ii) whether this becomes a repeatable template for Gilead’s pipeline build.
- Source: Fierce Biotech
|
|
2
|
FDA refuses to review Moderna's mRNA flu vaccine
|
- Follow-up: FDA’s refusal-to-file for Moderna’s mRNA flu vaccine (mRNA-1010) is still reverberating as industry groups warn about “moving goalposts” and increased regulatory uncertainty for novel modalities.
- Why it matters: Even if the underlying dispute is “just” comparator selection, the investor hit is real: it pushes out U.S. timing, raises perceived CBER unpredictability, and increases the discount rate applied to Moderna’s respiratory franchise pipeline cashflows.
- Source: BioSpace
- More: Reuters
|
| 3 | FDA issues CRL to Disc’s rare-disease program |
- FDA issued a Complete Response Letter to Disc for bitopertin in erythropoietic protoporphyria, questioning whether the magnitude of PPIX reduction is a reliable surrogate and whether biomarker changes translate to meaningful sunlight-tolerance benefit.
- Why it matters: Probability-weighted value takes a hit because FDA is effectively requiring a clinical-endpoint dataset (not just biomarker) for approval — pushing timelines and increasing execution risk. The key swing factor now is Disc’s ongoing Phase 3 APOLLO readout; positive clinical endpoints there can “re-open” the path, but investors will discount until FDA alignment on the resubmission package is clearer.
- Source: Reuters
- More: BioSpace
|
Everything Else that broke
- Basilea reports strong 2025 full-year results, beats guidance. — PR
- Inventiva reports preliminary FY2025 financial results. — PR
- Roche announces new head of Pharma Research and Early Development. — PR
- Pazdur comments on FDA trial requirements debate. — BioSpace
- CDC acting director departs HHS, leaving leadership void. — BioSpace
- Novo Nordisk provides share repurchase program update. — PR
- Radiopharma sector races to secure Actinium-225 supply. — BioSpace
- Biopharma faces fetal bovine serum supply squeeze. — BioSpace
- Pharma patent cliff outlook for 2026–2032. — Labiotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- Gilead strikes $1.5B synthetic lethal therapy deal with Genhouse. — Fierce Biotech
- Danaher is reportedly closing in on a ~$10B deal for Masimo (patient monitoring), per FT. — Reuters
VC / Private Financings
- No notable VC / private rounds announced since yesterday’s issue.
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours.
Academic Corner
- DOPA decarboxylase levels in the cerebrospinal fluid as a diagnostic marker of Lewy body disorders. — Nature Medicine
- Neurodegenerative diseases need more mechanism-informed trials. — Nature Medicine
- A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. — Nature Medicine
- TIGIT’s immuno-oncology teachings. — Nature RDD
|
